CareDx (CDNA) Earns Daily Media Impact Score of 0.12

Media coverage about CareDx (NASDAQ:CDNA) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CareDx earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.6402630326884 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern’s analysis:

Shares of CareDx (NASDAQ CDNA) traded up $0.58 during trading on Friday, reaching $7.18. 222,262 shares of the company’s stock were exchanged, compared to its average volume of 305,315. The company has a quick ratio of 0.35, a current ratio of 0.55 and a debt-to-equity ratio of -124.53. CareDx has a 12-month low of $0.76 and a 12-month high of $7.98.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. CareDx had a negative net margin of 84.14% and a negative return on equity of 157.00%. The firm had revenue of $12.19 million during the quarter, compared to the consensus estimate of $12.05 million. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. equities research analysts expect that CareDx will post -0.83 earnings per share for the current fiscal year.

A number of research firms recently issued reports on CDNA. Zacks Investment Research upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a research note on Tuesday, September 12th. ValuEngine upgraded shares of CareDx from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 24th. HC Wainwright began coverage on shares of CareDx in a report on Monday, November 27th. They issued a “buy” rating and a $12.00 price target for the company. Piper Jaffray Companies reissued an “overweight” rating and issued a $7.00 price target (up from $3.00) on shares of CareDx in a report on Tuesday, September 26th. Finally, Raymond James Financial raised shares of CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price target for the company in a report on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. CareDx currently has a consensus rating of “Buy” and an average target price of $7.75.

In related news, major shareholder Neil Gagnon purchased 10,642 shares of CareDx stock in a transaction on Thursday, October 5th. The stock was purchased at an average cost of $4.00 per share, with a total value of $42,568.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider James P. Yee sold 29,197 shares of the stock in a transaction on Friday, December 8th. The shares were sold at an average price of $7.00, for a total transaction of $204,379.00. Following the completion of the sale, the insider now directly owns 74,795 shares of the company’s stock, valued at $523,565. The disclosure for this sale can be found here. 5.40% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply